Mitapivat pediatric thalassemia trial, Agios study

Agios Pharmaceuticals registered a new pediatric thalassemia clinical trial on ClinicalTrials.gov under identifier NCT07506863. The study will evaluate mitapivat, a pyruvate kinase R (PKR) activator, in pediatric patients with thalassemia. The trial registration includes study design parameters, eligibility criteria, and enrollment information.\n\nPharmaceutical companies conducting similar research, healthcare providers treating thalassemia patients, and families seeking trial participation opportunities should consult the ClinicalTrials.gov registry for current study status, eligibility requirements, and investigator contact information. Trial sponsors should ensure their pediatric thalassemia programs are accurately reflected in registry databases.